I too was bemused by the market response to the trial results. I was expecting a rerate the day they were announced and was amazed by the response. Short term share price weakness such as we have been experiencing since those results came out do not phase a LT holder like me, however I am very disappointed I didn't have spare cash to grab more shares while they were so ridiculously cheap. Since having kids our combined income has dropped by over 60% so no spare cash for shares for the time being.
While a tiny 10 person trial achieving a CR may not be "statistically significant", I take the continued improvement of at least 2 patients since the trial results were initially published as very good news. A CR on a patient with metastasized gastric cancer is pretty amazing IMO, and I don't expect this is a statistical anomaly but rather a sign of bigger things to come. I await our Ph2 results with bated breath, and hope I can scrape together a few dollars for more shares before they appreciate.
IMU Price at posting:
2.0¢ Sentiment: Buy Disclosure: Held
(20min delay)
